Biomarin Pharmaceutical Inc. - Registered Shares
BMRN
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.76B
Close$
$93.94
67.6% upsideBiomarin Pharmaceutical - Registered Shares Target Price Details
Target Price by Analysts
67.6% upsideBiomarin Pharmaceutical - Registered Shares Target Price Details$156.91179.9% upside
Current Fair Value
179.9% upsideUndervalued by 179.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.76 Billion |
|---|---|
| Enterprise Value | $15.09 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.82 |
| Beta | 0.22 |
| Outstanding Shares | 192,959,000 |
Return
| Return on Equity | 1.15% |
|---|---|
| Return on Assets | 0.62% |
| Return on Invested Capital | 0.76% |
Valuation & Multiples
| P/E Ratio | 144.2 |
|---|---|
| PEG | -177.17 |
| Price to Sales | 3.3 |
| Price to Book Ratio | 1.75 |
| Enterprise Value to Revenue | 4.43 |
| Enterprise Value to EBIT | 198.04 |
| Enterprise Value to Net Income | 206 |
| Total Debt to Enterprise | 0.28 |
| Debt to Equity | 0.66 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$0.95
Average shareholder expectationRevenue Estimate
$932.03 M
Average shareholder expectationNext Earnings Call
Expected Date
October 26, 2026
EPS Estimate
$1.35
Average shareholder expectationRevenue Estimate
$1.02 B
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 36.98% |
|---|---|
| Total Calls | 500▼ 99.97% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.04%▼ 101.29% |
|---|---|
| Total Invested | $5.01M▼ 99.96% |
| Investors Holding | 18▼ 569.00% |
ESG Score
No data
About Biomarin Pharmaceutical Inc.
3,221 employees
CEO: Jean-Jacques Bienaime BioMarin Pharmaceutical Inc. specializes in the development and commercialization of therapeutic solutions for individuals grappling with severe and life-threatening rare diseases. Its array of market-ready products features Vimizim, an ...